Surgery Department, Hospital Universitario Mayor - Méderi, Bogotá, Colombia.
Universidad del Rosario, Bogotá, Colombia.
BMC Surg. 2024 Mar 12;24(1):87. doi: 10.1186/s12893-024-02383-6.
The laparoscopic cholecystectomy is the treatment of choice for patients with benign biliary disease. It is necessary to evaluate survival after laparoscopic cholecystectomy in patients over 80 years old to determine whether the long-term mortality rate is higher than the reported recurrence rate. If so, this age group could benefit from a more conservative approach, such as antibiotic treatment or cholecystostomy. Therefore, the aim of this study was to evaluate the factors associated with 2 years survival after laparoscopic cholecystectomy in patients over 80 years old.
We conducted a retrospective observational cohort study. We included all patients over 80 years old who underwent laparoscopic cholecystectomy. Survival analysis was conducted using the Kaplan‒Meier method. Cox regression analysis was implemented to determine potential factors associated with mortality at 24 months.
A total of 144 patients were included in the study, of whom 37 (25.69%) died at the two-year follow-up. Survival curves were compared for different ASA groups, showing a higher proportion of survivors at two years among patients classified as ASA 1-2 at 87.50% compared to ASA 3-4 at 63.75% (p = 0.001). An ASA score of 3-4 was identified as a statistically significant factor associated with mortality, indicating a higher risk (HR: 2.71, CI95%:1.20-6.14).
ASA 3-4 patients may benefit from conservative management due to their higher risk of mortality at 2 years and a lower probability of disease recurrence.
腹腔镜胆囊切除术是治疗良性胆道疾病患者的首选方法。有必要评估 80 岁以上患者行腹腔镜胆囊切除术后的生存情况,以确定长期死亡率是否高于报道的复发率。如果是这样,该年龄组可能受益于更保守的治疗方法,如抗生素治疗或胆囊造口术。因此,本研究旨在评估 80 岁以上患者行腹腔镜胆囊切除术后 2 年生存的相关因素。
我们进行了一项回顾性观察性队列研究。我们纳入了所有 80 岁以上行腹腔镜胆囊切除术的患者。采用 Kaplan-Meier 法进行生存分析。采用 Cox 回归分析确定与 24 个月死亡率相关的潜在因素。
共纳入 144 例患者,其中 37 例(25.69%)在两年随访时死亡。不同 ASA 组的生存曲线进行了比较,ASA 1-2 级患者的两年生存率为 87.50%,明显高于 ASA 3-4 级患者的 63.75%(p=0.001)。ASA 评分 3-4 级是与死亡率相关的统计学显著因素,表明风险更高(HR:2.71,95%CI:1.20-6.14)。
ASA 3-4 级患者可能受益于保守治疗,因为他们在 2 年内的死亡率较高,且疾病复发的可能性较低。